『Oxford and Serum Institute Launch R78C Next-Generation Malaria Vaccine to Transform Treatment Across Africa』のカバーアート

Oxford and Serum Institute Launch R78C Next-Generation Malaria Vaccine to Transform Treatment Across Africa

Oxford and Serum Institute Launch R78C Next-Generation Malaria Vaccine to Transform Treatment Across Africa

無料で聴く

ポッドキャストの詳細を見る

今ならプレミアムプランが3カ月 月額99円

2026年5月12日まで。4か月目以降は月額1,500円で自動更新します。

概要

 The University of Oxford and Serum Institute of India have announced a landmark partnership to develop R78C, a next-generation malaria vaccine targeting multiple stages of the Plasmodium falciparum parasite's lifecycle, according to NDTV reports. This licensing agreement aims to accelerate clinical trials, large-scale manufacturing, and potential rollout, with experts noting its potential for stronger immune responses, longer protection, and reduced transmission compared to earlier vaccines like RTS,S and R21.

R78C focuses on blood-stage antigens RIPR and CyRPA, addressing the phase when symptoms peak and severity rises, unlike prior shots that primarily hit the sporozoite entry stage. NDTV highlights that Serum Institute's manufacturing prowess could make the vaccine affordable for widespread use in high-burden areas. While still in early development, the collaboration signals a shift toward multi-stage strategies to overcome limitations of existing vaccines, both WHO-prequalified.

In Cameroon, ongoing malaria vaccine rollouts are yielding positive results, as shared in an Africanews report. Mothers report significant health improvements in children after receiving doses, with about 60 percent getting at least three shots in 2025. Health officials note strong acceptance and efficacy when combined with preventive measures, though fourth-dose uptake needs boosting; regional cases dropped 50 percent alongside rising vaccine coverage from 70 to 89 percent, per Malariaworld data.

The World Health Organization recently prequalified the first malaria treatment tailored for newborns and infants weighing two to five kilograms—artemether-lumefantrine in a safer formulation—days after World Malaria Day, according to a WHO update covered in video news. This addresses dosing risks for vulnerable babies in Africa, where 30 million are born yearly in endemic zones, enabling broader procurement.

WHO also approved three new rapid diagnostic tests targeting pf-LDH protein to counter HRP2-deletion strains evading traditional tests, vital in regions like the Horn of Africa where up to 80 percent of cases were missed. These advances build on vaccines saving 14 million lives since 2000, underscoring momentum against a disease claiming hundreds of thousands annually.

This content was created in partnership and with the help of Artificial Intelligence AI

This episode includes AI-generated content.
まだレビューはありません